AGIO Agios Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AGIO

Price (delayed)

$29.045

Market cap

$1.73B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.25

Enterprise value

$1.65B

?
Relative Growth: Rel. Growth: 46
Relative Strength: Rel. Strength: 29
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 21

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In ...

Highlights
Agios Pharmaceuticals's gross profit has surged by 83% YoY and by 25% QoQ
The revenue has surged by 78% year-on-year and by 22% since the previous quarter
The quick ratio is down by 25% year-on-year but it is up by 22% since the previous quarter
AGIO's net income has shrunk by 163% YoY and by 2.4% QoQ
Agios Pharmaceuticals's EPS has shrunk by 162% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.agios.com
Peers: XNCR EXEL BMRN PFE

Key stats

What are the main financial stats of AGIO

AGIO stock price

How has the Agios Pharmaceuticals stock price performed over time
Intraday
4.93%
1 week
-4.52%
1 month
5.39%
1 year
-14.65%
YTD
6.7%
QTD
-14.14%

Financial performance

How have Agios Pharmaceuticals's revenue and profit performed over time
Revenue
$66.05M
Gross profit
$59.47M
Operating income
-$475.53M
Net income
-$422.6M
Gross margin
90%
Net margin
-639.8%
AGIO's net income has shrunk by 163% YoY and by 2.4% QoQ
The operating margin has dropped by 159% year-on-year but it has increased by 18% since the previous quarter
The net margin has dropped by 136% year-on-year but it has grown by 16% since the previous quarter
Agios Pharmaceuticals's gross profit has surged by 83% YoY and by 25% QoQ

Price vs fundamentals

How does AGIO's price correlate with its fundamentals

Growth

What is Agios Pharmaceuticals's growth rate over time

Valuation

What is Agios Pharmaceuticals stock price valuation
AGIO P/E details
P/E
N/A
P/B
1.53
P/S
25.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.97
Agios Pharmaceuticals's EPS has shrunk by 162% YoY
Agios Pharmaceuticals's equity has decreased by 24% YoY and by 7% QoQ
The P/B is 9% below the 5-year quarterly average of 1.6 and 9% below the last 4 quarters average of 1.6
AGIO's P/S is 86% below its 5-year quarterly average of 181.0 and 38% below its last 4 quarters average of 39.6
The revenue has surged by 78% year-on-year and by 22% since the previous quarter

Efficiency

How efficient is Agios Pharmaceuticals business performance
The ROA has plunged by 169% YoY and by 10% from the previous quarter
AGIO's return on equity has dropped by 168% year-on-year and by 10% since the previous quarter
The company's return on invested capital has shrunk by 164% YoY and by 11% QoQ
Agios Pharmaceuticals's return on sales has shrunk by 133% YoY but it has increased by 16% QoQ

Dividends

What is AGIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGIO.

Financial health

How did Agios Pharmaceuticals financials performed over time
The total liabilities has declined by 27% since the previous quarter and by 15% year-on-year
The quick ratio is down by 25% year-on-year but it is up by 22% since the previous quarter
The debt is 97% smaller than the equity
The debt has declined by 32% year-on-year and by 11% since the previous quarter
The debt to equity has decreased by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.